BioSpace News Archive

Drug Development

Faraday Pharmaceuticals Announces Publication of Results from its Phase 2 Study of FDY-5301 for the Treatment of Reperfusion Injury Following a STEMI Heart AttackTo be Published in the International Journal of Cardiology

Faraday Pharmaceuticals, Inc. announced today the publication of results from its Phase 2 trial of FDY-5301 for the treatment of reperfusion injury following an ST-elevation myocardial infarction (STEMI) in the January 15, 2022 issue of the International Journal of Cardiology.

December 27, 2021
·
3 min read
Genetown

Moderna Announces Switzerland Exercises its Option to Purchase Seven Million Additional Doses of Moderna’s COVID-19 Booster Vaccine in 2022

Moderna, Inc. today announced that the Swiss Federal Government has exercised its option to purchase an additional seven million doses of Moderna’s booster vaccine for delivery in the second half of 2022.

December 27, 2021
·
3 min read
Aveanna to Virtually Participate at the JP Morgan Healthcare Conference

Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team will virtually attend the JP Morgan Healthcare conference held on January 12th. The presentation will begin at 11:15 AM Eastern Time.

December 27, 2021
·
1 min read
Business

DANAHER SCHEDULES FOURTH QUARTER 2021 EARNINGS CONFERENCE CALL

Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the fourth quarter 2021 on Thursday, January 27, 2022 beginning at 8:00 a.m. ET and lasting approximately 1 hour.

December 27, 2021
·
1 min read
Drug Development

Cyrus Biotechnology’s COVID therapeutic lead, ACE2.v2.4, strongly binds and neutralizes SARS-CoV-2 omicron variant potentially providing long term protection

Cyrus Biotechnology, Inc. today announced that its pre-clinical stage COVID therapeutic lead molecule, ACE2.v2.4 strongly binds the spike protein of SARS-CoV-2 variant of concern (VOC) omicron.

December 27, 2021
·
5 min read
Business

Microbot Medical Announces Strategic Collaboration with Stryker Corporation to Develop the LIBERTY® Robotic System for Neurovascular Applications

Microbot Medical Inc. (Nasdaq: MBOT) announced that it has entered into a strategic collaboration agreement with Stryker, a leading global medical technology company.

December 27, 2021
·
3 min read
Deals

Pardes Biosciences Debuts as a Publicly Traded Company Focused on Oral Antiviral Therapies to Potentially Treat and Prevent COVID-19

Gross proceeds made available to Pardes Biosciences from transaction totaled approximately $274 million, combining approximately $199 million of funds held in FS Development Corp.

December 27, 2021
·
7 min read
Business

Metacrine Announces Resignation of Chief Medical Officer

Metacrine, Inc. today announced that Hubert C. Chen, M.D., chief medical officer, has resigned to pursue a new opportunity.

December 27, 2021
·
2 min read
FDA

Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-001 in Development for the Treatment of AML

Celularity Inc. today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer (NK) cell therapy, CYNK-001.

December 27, 2021
·
5 min read
FDA

Nobel Biocare Receives FDA 510(k) Clearance for the Nobel Biocare N1™ Implant System

Envista Holdings Corporation (NYSE: NVST) (“Envista”) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Nobel Biocare N1™ implant system.

December 27, 2021
·
7 min read